A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer by Sparano, Joseph A. et al.
ARTICLE OPEN
A metastasis biomarker (MetaSite Breast™ Score) is
associated with distant recurrence in hormone receptor-
positive, HER2-negative early-stage breast cancer
Joseph A. Sparano1, Robert Gray2, Maja H. Oktay1, David Entenberg3, Thomas Rohan3, Xiaonan Xue3, Michael Donovan4,
Michael Peterson5, Anthony Shuber5, Douglas A. Hamilton5, Timothy D’Alfonso6, Lori J. Goldstein7, Frank Gertler8, Nancy E. Davidson9,
John Condeelis3 and Joan Jones3
Metastasis is the primary cause of death in early-stage breast cancer. We evaluated the association between a metastasis biomarker,
which we call “Tumor Microenviroment of Metastasis” (TMEM), and risk of recurrence. TMEM are microanatomic structures where
invasive tumor cells are in direct contact with endothelial cells and macrophages, and which serve as intravasation sites for tumor
cells into the circulation. We evaluated primary tumors from 600 patients with Stage I–III breast cancer treated with adjuvant
chemotherapy in trial E2197 (NCT00003519), plus endocrine therapy for hormone receptor (HR)+ disease. TMEM were identiﬁed
and enumerated using an analytically validated, fully automated digital pathology/image analysis method (MetaSite Breast™),
hereafter referred to as MetaSite Score (MS). The objectives were to determine the association between MS and distant relapse free
interval (DRFI) and relapse free interval (RFI). MS was not associated with tumor size or nodal status, and correlated poorly with
Oncotype DX Recurrence Score (r = 0.29) in 297 patients with HR+/HER2- disease. Proportional hazards models revealed a
signiﬁcant positive association between continuous MS and DRFI (p = 0.001) and RFI (p = 0.00006) in HR+/HER2- disease in years
0–5, and by MS tertiles for DRFI (p = 0.04) and RFI (p = 0.01), but not after year 5 or in triple negative or HER2+ disease. Multivariate
models in HR+/HER- disease including continuous MS, clinical covariates, and categorical Recurrence Score (<18, 18–30, > 30)
showed MS is an independent predictor for 5-year RFI (p = 0.05). MetaSite Score provides prognostic information for early
recurrence complementary to clinicopathologic features and Recurrence Score.
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INTRODUCTION
Metastasis is the primary cause of death in breast cancer, the most
frequently diagnosed cancer and the leading cause of cancer
death among women, accounting for 25% of the total cancer
cases (1.68 million) and 15% of the cancer deaths (520,000)
worldwide.1,2 Although breast cancer mortality rates have
declined due to screening and more effective adjuvant systemic
therapies,3 more accurately identifying metastatic risk in order to
minimize overtreatment or undertreatment, and developing new
approaches to prevent metastasis remain major clinical cha-
lenges.4 Elucidating the biology underpinning the metastatic
process offers one potential approach to addressing these
challenges.
Studies evaluating breast cancer cell dissemination at single cell
resolution using novel multiphoton imaging tools and mouse
models have shown that tumor cells stream toward blood
vessels.5 Collection of streaming tumor cells using an in vivo
invasion assay for gene expression proﬁling has led to the
identiﬁcation of the Invasion Signature and discovery of pathways
that are upregulated in streaming tumor cells with transendothe-
lial migration activity,6–15 which includes differential expression of
invasive Mena isoforms that regulate cancer cell streaming,
transendothelial migration, and ultimately intravasation of breast
tumor cells.16–21 A subpopulation of Mena-expressing comes into
direct contact with endothelial cells and macrophages, forming
microanatomic structures that we have called “Tumor MicroEnvir-
onment of Metastasis”, or “TMEM”, which serve as a doorway for
other streaming tumor cells to intravasate.22,23 TMEM are found in
primary human breast cancers, as well as regional lymph node
and distant metastases.24
TMEM structures may be identiﬁed in formalin-ﬁxed parafﬁn-
embedded human breast cancers by a triple immunostain
identifying where macrophages (anti-CD68), endothelial cells
(anti-CD31), and streaming tumor cells (anti-panMena) are in
direct contact.25,26 In an initial proof-of-concept case:control study
of 60 patients with early breast cancer, median TMEM Score was
signiﬁcantly higher in primary tumors in cases with distant
recurrence compared with controls without distant recurrence
(median TMEM density 150 vs. 50, p = 0.00006).25 Moreover, in a
case–control study of 259 case–control pairs nested in a large
population-based study of early-stage breast cancer patients,
TMEM Score was positively associated with risk of distant
recurrence in estrogen receptor (ER) + , HER2- disease when
evaluated in multivariate model including tumor size, nodal status,
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grade and IHC4 Score (odds ratio 2.67, p = 0.004 for highest vs.
lowest tertile), and did not correlate with tumor size, nodal status,
grade, or IHC4.26 In another report, TMEM Score did not correlate
Oncotype Recurrence Score.24
Based on this initial evidence indicating a strong association
between TMEM Score and distant metastasis in ER+, HER2-
negative breast cancer, we undertook another study to conﬁrm
the association between TMEM Score and recurrence in this breast
cancer subtype, and to explore the association in triple negative
and HER2+ breast cancer. We used a prospective-retrospective
study design that utilized biospecimens from a well annotated
and uniformly treated clinical trial cohort, an approach that
provides a high level of evidence supporting the clinical validity of
a biomarker.27 The study population included 600 patients with
high-risk stage I–III breast cancer and 0–3 positive axillary nodes
who all received standard chemotherapy, plus endocrine therapy
if the tumor was hormone receptor (HR) positive.28 In a subset of
297 patients with HR+/HER2- breast cancer, we also evaluated risk
of metastasis in association with TMEM Score in joint models
including the Oncotype DX Recurrence Score, a widely used
multiparameter gene expression assay that has shown clinical
validity and utility in this population,29 and in a prospectively
conducted clinical trial.30 Moreover, we used a fully automated
and scalable clinical assay for identiﬁcation and enumeration of
TMEM (MetaSite Breast™) utilizing digital pathology methods
coupled with image analysis, which demonstrated high analytical
accuracy, reproducibility, and precision,31 and hence use the term
MetaSite Score to describe the assay results in this report.
RESULTS
MetaSite Score in overall cohort and by breast cancer subtype
The characteristics of the study cohort, overall and by breast
cancer subtype, is shown in Table 1. The MetaSite Score in all 600
cases ranged from of 0 to 199, and the weighted mean MetaSite
Score was 19.9. The weighted mean MetaSite Score was
signiﬁcantly lower in the HR+/HER2- subtype than in the triple
negative subtype (16.1 vs. 23.8, p = 0.001) or the HER2+ subtype
(16.1 vs. 26.2, p = 0.003), while the difference between triple
negative and HER2+ was not signiﬁcant (23.8 vs. 26.2, p = 0.59). As
expected, virtually all patients with triple negative disease (99.5%)
and most with HER2+ disease (69%) had a high Recurrence Score
of >30 because low ER and high HER2 expression contribute to a
higher Recurrence Score.29
Clinicopathologic features by empirical MetaSite tertile group
The empirical tertile cutpoints for the entire cohort in the
weighted distribution were 0 to 5 (190 cases, weighted percent
33.3%), 6 to 17 (196 cases, weighted percent 33.5%) and 18 to 199
(214 cases, weighted percent 33.2%). The characteristics of
patients in each MetaSite Score empirical tertile group are shown
in Table 2. There were signiﬁcant differences in MetaSite Score
tertile distribution (high, intermediate, low MetaSite Score) for age
40 or younger (37% vs. 31% vs. 21%, p = 0.02) and older than 60
years (34% vs. 31% vs. 49%, p = 0.04), ER (48%, vs. 70% vs 67%, p <
0.001) and PR (49% vs. 65% vs. 68%, p < 0.001) expression, and any
grade (6% vs. 18% vs. 62% for low grade, p < 0.001; 20% vs. 40%
vs. 44% for intermediate grade, p < 0.001; 73% vs. 42% vs. 28% for
high grade, p < 0.001), but not tumor size or axillary nodal
metastases. These ﬁndings are consistent with the observation of
signiﬁcantly higher MetaSite Scores in the triple negative and
HER2+ compared with HR+/HER2- breast cancer.
Relationship between MetaSite Score and Recurrence or Survival
The proportional hazards model including only MetaSite Score as
a continuous covariate and the time-varying coefﬁcient model
that adds the variable time*MetaSite Score was ﬁt overall and for
each of the three breast cancer subtypes. Although there was no
signiﬁcant association between MetaSite Score and distant
recurrence overall, there was strong evidence of an effect in the
time-varying coefﬁcient model in the HR+/HER2- group (p =
0.0002, two degree-of-freedom overall test for association), and
the hazards were not proportional over time (p = 0.01) (Supple-
mental Table 1). A nearly signiﬁcant association was also noted
between MetaSite Score and breast cancer speciﬁc survival (p =
0.06) but not overall survival (OS) (p = 0.21) in the HR+/HER2-
group in the time-varying coefﬁcient model, which may be
explained by the high proportion of deaths in this group that were
not due to breast cancer (48/85 [56%]). The association between
MetaSite Score and breast cancer death was not signiﬁcantly time-
dependent in the time-varying coefﬁcient model (p = 0.54), but
was signiﬁcantly associated with breast cancer death in the
proportional hazards model not adjusted for time (p = 0.04).
In order to further evaluate the time-dependent effect for
distant recurrence, the association between MetaSite Score and
recurrence was evaluated using follow-up time intervals 0–5 years
and 5–10 years, with no adjustment for other factors. Shown in
Table 3 are the p-values and estimated coefﬁcients for association
of continuous MetaSite Score and risk of recurrence. A strong
association was seen in the HR+/HER2- subtype in the 0–5 year
period for distant relapse free interval (DRFI) (p = 0.001) and
relapse free interval (RFI) (P = 0.00006), but not triple negative or
HER2 + disease. The estimated coefﬁcient was negative (and
statistically non-signiﬁcant) in all of the subsets in the 5–10 year
period, suggesting that any effects are limited to the earlier time
period. Kaplan–Meier analysis revealed a signiﬁcant association
between MetaSite Score and DRFI (p = 0.04) and RFI (p = 0.01) in
the HR+/HER2- group when evaluated by empirical tertiles (</ = 5,
6–17, > / = 18) for the entire cohort with follow-up truncated at 5
years (Fig. 1a–b).
Relationship between Recurrence Score and Recurrence, and
between MetaSite Score and Recurrence Score
In the 297 patients with HR+/HER2- disease, Recurrence Score was
prognostic at 10 years when using classical cutpoints (<18, 18–30,
or > 30) for DRFI (p = 0.0003) and RFI (p = 0.0004), and also when
using TAILORx cutpoints (<11, 11–25, > 25) for DRFI (p = 0.007) and
RFI (p = 0.003), although there was somewhat better separation
among the low, intermediate, and high-risk categories using the
latter deﬁnition (Supplemental Fig. 1A–D); results were similar if
analysis was truncated at 5 years of follow-up (data not shown).
The scatter plots of MetaSite Score by Recurrence Score are
given in Fig. 2, showing poor correlation. The raw Pearson
correlation between the continuous MetaSite Score and Recur-
rence Score is 0.27 in the overall sample and 0.29 in the HR
+/HER2- subtype. Although MetaSite Score and Recurrence Score
are both prognostic for recurrence in this cohort, they are only
weakly correlated with each other. Figure 2 also shows individuals
who had a recurrence or distant recurrence within the ﬁrst 5 years,
which accounted for the majority or recurrences (43 of 70 [61%])
and distant recurrences (35 of 49 [71%]) in the HR+/HER2- cohort
(Supplemental Table 2). The ﬁgure illustrates a wide range of
MetaSite scores within each Recurrence Score group, including the
mid-range Recurrence Scores, however deﬁned.
Multivariate models in HR+, HER2- breast cancer subtype
Because the association between MetaSite Score and recurrence
was time-dependent, proportional hazards models for DRFI and
RFI in the HR+/HER2- subset using follow-up through 5 years were
ﬁt (Table 4). Clinical covariates including axillary nodal status
(negative vs. positive), tumor size (</=2 cm vs. >2 cm) and grade
(high vs. intermediate vs. low) were included in all models.
MetaSite Score (continuous linear variable) showed a signiﬁcant
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association with RFI (p = 0.04) and borderline association with DRFI
(p = 0.08). If Recurrence Score (continuous linear variable) was
included in the model instead of MetaSite Score, it was not
signiﬁcant for RFI (p = 0.51) or for DRFI (p = 0.90). If categorical
Recurrence Score (<18, 18–30, >30) was added to the model
including MetaSite Score (continuous linear variable) and clinical
covariates, there remained signiﬁcant association with RFI (p =
0.05) and a borderline association with DRFI (p = 0.10). If
categorical rather than continuous MetaSite Score was used in
the model, the association was not signiﬁcant.
Prognosis associated with MetaSite Score by Recurrence Score
category
The complementary prognostic information provided by MetaSite
Score was further examined by evaluating the hazard ratio for
recurrence by Recurrence Score categories of low, intermediate
and high risk, using both the classical (Fig. 3a) and TAILORx
deﬁnitions in the HR+/HER2- group (Fig. 3b). Higher MetaSite
Score (upper tertile vs. lower tertile) was associated with a 9.7-fold
higher risk of distant recurrence (95% conﬁdence intervals [CI] 1.8,
54.1) and 6.1-fold higher risk of overall recurrence (95% CI 1.3,
27.8) if the Recurrence Score was <18, but did not provide
additional information for the intermediate or high Recurrence
Score groups using the classical cutpoints (Fig. 3a). If the TAILORx
cutpoints were used, there were too few recurrences to evaluate
the contribution of MetaSite Score, although higher MetaSite
Score was associated with a 3.9-fold higher risk of distant
recurrence (95% CI 1.2, 12.9) in the group that had a mid-range
Recurrence Score of 11–25 (Fig. 3b).
DISCUSSION
Using high-resolution two-photon microscopy in the MMTV-PyMT
mammary carcinoma and patient-derived xenograft models, we
have shown that: (1) transient blood vessel permeability induced
by vascular endothelial growth factor (VEGF) and accompanying
tumor cell intravasation occur exclusively at TMEM sites, (2) TMEM-
associated macrophages are a subpopulation of tumor-associated
macrophages that are pro-angiogenic (TIE2Hi/VEGFHi), and (3)
secretion of VEGF from TMEM macrophages leads to TMEM-
Table 1. Distribution of clinicopathologic factors and mean weighted Metasite Scores by breast cancer subtype
Triple negative HR+/HER2- HER2+ Total
# (n= 200) Weighted % # (n= 297) Weighted % # (n= 103) Weighted % # (n= 600) Weighted %
Age (years)
<=40 42 22.7% 33 10.8% 14 13.2% 89 14.4%
41–50 77 40.6% 96 32.9% 39 39.7% 212 36.1%
51–60 53 24.1% 102 35.6% 30 28.4% 185 31.3%
>60 28 12.6% 66 20.7% 20 18.8% 114 18.2%
Premenopausal 107 56.4% 129 43.3% 46 45.8% 282 47.3%
Central ER/PR IHC
ER-positive 0 0% 264 90.5% 57 65.7% 321 61.7%
PR-positive 0 0% 273 91.8% 47 54.8% 320 60.7%
Tumor size
<=2 cm 83 44.0% 157 54.4% 44 45.4% 284 50.1%
2.1 to 5.0 cm 108 52.1% 131 42.1% 53 50.6% 292 46.2%
>5 cm 9 3.9% 9 3.5% 6 4.0% 24 3.7%
Axillary nodal status
Node negative 148 80.9% 145 54.3% 63 67.9% 356 63.8%
1–3 positive nodes 52 19.1% 152 45.7% 40 32.1% 244 36.2%
Central grade
Low 2 1.1% 77 27.7% 6 8.0% 85 17.2%
Intermediate 18 9.0% 141 48.8% 28 30.9% 187 35.0%
High 180 89.9% 79 23.5% 69 61.1% 328 47.8%
Recurrence Score
<18 0 0% 153 54.1% 13 17.7% 166 33.3%
18–30 1 0.5% 94 31.5% 10 13.3% 105 20.0%
>30 199 99.5% 50 14.4% 80 69.0% 329 46.7%
Treatment arm
AT 89 48.8% 170 51.4% 51 47.2% 310 50.0%
AC 111 51.2% 127 48.6% 52 (58.8%) 290 50.0%
MetaSite Score
Weighted mean – 23.8 – 16.1 – 26.2 – 19.9
ER/PR/HER2 classiﬁcation: 2/600 cases did not have central immunohistochemistry (IHC) available, but local IHC and gene expression results were concordant
for these two cases, so they were included and classiﬁed based on those results (one case HR+/HER2- and one case TN). ER/PR was classiﬁed as positive for
Allred Score of 3 or higher as described in ref. 49 HER2 expression was classiﬁed in a central lab as positive if 3 + by IHC or FISH ampliﬁcation by 2007 ASC0-
CAP guidelines48
AT doxorubicin/docetaxel, AC doxorubicin/cyclophosphamide
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associated transient blood vessel permeability, tumor cell
intravasation, and an increase in circulating tumor cells.23 Prior
proof-of-concept studies indicated that TMEM structures could be
identiﬁed in human breast cancer using a triple immunohisto-
chemical stain for Mena over-expressing tumor cells, macro-
phages, and endothelial cells all in direct contact,25 and that
identiﬁcation and enumeration of TMEM structures by manual
methods was prognostic for distant recurrence in HR+/HER2-
breast cancer independent of classical clinicopathologic features
using primary tumor samples derived from a population-based
cohort.26 Here, we report a second prospective-retrospective
biomarker study conﬁrming the clinical validity of the association
between TMEM Score and distant recurrence, speciﬁcally early
recurrence within 5 years of diagnosis, now in a uniformly treated
clinical trial cohort of patients with HR+/HER2- early-stage breast
cancer using an automated, high-throughput analytically vali-
dated assay (MetaSite Breast™) in a Clinical Laboratory Improve-
ment Amendments (CLIA)-certiﬁed clinical diagnostic laboratory;
hence, we use the term MetaSite Score to describe the assay and
results here. Although MetaSite Score was not prognostic in triple
negative or HER2+ breast cancer in this cohort, it is noteworthy
that the scores were signiﬁcantly higher in this high-risk subtypes
compared with HR+/HER2-negative disease, which is consistent
with the hypothesis that higher TMEM Score is associated with
greater distant recurrence risk. Potential explanations for lack of
prognostic association in poor risk breast cancer subtypes include
the relatively small sample size and limited statistical power for
these subtypes, and a threshold effect below which TMEM Score is
Table 2. Distribution of clinicopathologic factors by empirical tertile of Metasite Score
MetaSite Score MetaSite Score MetaSite Score
0–5 6–17 18–199
# (n= 190) Weighted % # (n= 196) Weighted % # (n= 214) Weighted % p-value
Age (years)
<=40 21 9.3% 31 15.0% 37 19.0% 0.02
41–50 56 31.2% 78 40.6% 78 36.4% 0.21
51–60 64 34.8% 56 29.3% 65 29.8% 0.51
>60 49 24.6% 31 15.1% 34 14.8% 0.04
Premenopausal 75 40.6% 100 51.2% 107 50.0% 0.11
Central ER/PR IHC
ER-positive 114 67.3% 118 69.5% 89 48.2% <0.001
PR-positive 115 68.0% 111 65.1% 94 48.9% <0.001
Tumor size
<=2 cm 98 53.8% 91 49.1% 95 47.3% 0.45
2.1 to 5.0 cm 83 42.7% 98 46.9% 111 49.1% 0.47
>5 cm 9 3.5% 7 4.1% 8 3.6% 0.96
Axillary nodal status
Node negative 111 61.8% 115 62.0% 130 67.6% 0.35
Central grade
Low 46 27.4% 29 17.8% 10 6.3% <0.001
Intermediate 77 44.2% 72 40.3% 38 20.3% <0.001
High 67 28.4% 95 41.8% 166 73.4% <0.001
p-values are for comparison of the weighted proportion in the three MetaSite groups for each row
Table 3. Estimated association between continuous Metasite Score and risk of Distant Recurrence or any Recurrence
0–5 Years 5–10 Years Time by MetaSite p-value
Group Endpoint Estimated coefﬁcienta p-value Estimated coefﬁcienta p-value
Overall DRFI 0.0062 0.10 −0.017 0.23 0.11
RFI 0.0084 0.005 −0.0061 0.45 0.09
Triple negative DRFI −0.0081 0.34 – – –
RFI −0.0049 0.48 – – –
HR+/HER2- DRFI 0.014 0.001 −0.0022 0.86 0.21
RFI 0.015 0.00006 −0.0062 0.56 0.05
HER2+ DRFI −0.0022 0.81 −0.082 0.16 0.18
RFI 0.0040 0.53 −0.081 0.11 0.09
a Estimated coefﬁcient is the slope of the MetaSite Score variable in the proportional hazards model, which is the log hazard ratio for a 1-unit increase in the
MetaSite Score value
MetaSite score is prognostic in ER-positive breast cancer
JA Sparano et al.
4
npj Breast Cancer (2017)  42 Published in partnership with the Breast Cancer Research Foundation
prognostic, and above which higher TMEM Score is not associated
with higher recurrence risk.
Another objective of this study was to evaluate whether
MetaSite Score provided clinically useful prognostic information
beyond that provided by Recurrence Score. Here, we show for the
ﬁrst time that MetaSite Score correlates poorly with Recurrence
Score and provides complementary prognostic information for
early recurrence, including patients with a mid-range Recurrence
Score for whom uncertainty still exists about the beneﬁt of
chemotherapy.4 Three trials are currently evaluating the role of
chemotherapy in patients with a mid-range Recurrence Score,
including TAILORx (NCT00310180) in node-negative disease and
an Recurrence Score of 11–25, and the RxPONDER
(NCT01272037)32 and OPTIMA (ISRCTN42400492) trials in patients
with up to nine positive axillary nodes and low to mid-range
Recurrence Score (</=25).33,34
Because TMEM are believed to serve as the doorway for
hematogenous dissemination and distant metastasis, the primary
study endpoint in this analysis was distant recurrence as a ﬁrst
event, which accounted for 70% of the recurrences; the remaining
30% were localregional recurrences without concurrent distant
recurrence as a ﬁrst event. A limitation of our study was that distant
recurrence occurring after localregional recurrence was not
recorded, thus potentially underestimating the proportion of
patients who eventually developed a distant recurrence. Isolated
localregional recurrence without concurrent distant recurrence is
known to be associated with a high risk of subsequent distant
recurrence and breast cancer mortality.35 Thus, although there was
only a borderline association between MetaSite Score and distant
recurrence in the multivariate models including clinical covariates
Fig. 1 a Distant relapse free interval (DRFI) by MetaSite Score
empirical tertile groups in hormone receptor-positive, HER2-
negative disease (P05: p-value computed truncating follow-up at 5
years). b Relapse free interval (RFI) by MetaSite Score empirical
tertile groups, in hormone receptor-positive, HER2-negative disease
(P05: p-value computed truncating follow-up at 5 years)
Fig. 2 Correlation between MetaSite Score and Recurrence Score
with both MetaSite Score and Recurrence Score (raw Pearson
correlation r= 0.29) truncated at 50 (with all scores above 50 shown
as 50). Recurrences occurring within 5 years are shown in colors,
including all recurrences (RFI) and distant recurrences (DRFI)
Table 4. Log hazard ratios (LHR), standard errors (SE) and p-values (P)
from multi-factor models for DRFI and RFI using follow-up through 5
years
DRFI RFI
LHR (SE) p LHR (SE) p
Model 1:
Node Pos vs. Neg 0.43 (0.26) 0.10 0.42 (0.22) 0.06
Tumor size<=2 cm vs. >2 0.60 (0.37) 0.11 0.40 (0.33) 0.23
Grade Mod vs. Well 0.64 (0.54) 0.31 0.56 (0.50) 0.13
Poor vs. Well 0.96 (0.64) 1.12 (0.56)
Continuous MetaSite Score 0.011 (0.006) 0.08 0.011 (0.005) 0.04
Model 2:
Node Pos vs. Neg 0.39 (0.26) 0.14 0.40 (0.22) 0.07
Tumor size<=2 cm vs. >2 0.62 (0.37) 0.10 0.40 (0.33) 0.23
Grade Mod vs. Well 0.70 (0.54) 0.21 0.59 (0.50) 0.13
Poor vs. Well 1.30 (0.74) 1.30 (0.64)
Continuous Recurrence Score 0.002 (0.017) 0.90 0.009 (0.014) 0.51
Model 3:
Node Pos vs. Neg 0.54 (0.28) 0.05 0.52 (0.23) 0.03
Tumor size<=2 cm vs. >2 0.55 (0.38) 0.15 0.35 (0.34) 0.30
Grade Mod vs. Well 0.44 (0.55) 0.71 0.35 (0.51) 0.67
Poor vs. Well 0.55 (0.80) 0.61 (0.70)
RS 18–30 vs. <18 0.85 (0.49) 0.18 0.91 (0.45) 0.13
> 30 vs. <18 0.57 (0.79) 0.79 (0.67)
Continuous MetaSite Score 0.010 (0.006) 0.10 0.010 (0.005) 0.05
The three models differ only in the modeling of MetaSite Score and
Recurrence Score. Model 1 includes only continuous MetaSite Score, Model
2 only continuous Recurrence Score, and Model 3 includes both
categorical Recurrence Score. p-values for Grade and Categorical Recur-
rence Score are for any differences among the three categories
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and categorical Recurrence Score, the signiﬁcant association
between MetaSite Score and all recurrences supports the robust-
ness of the prognostic information provided by MetaSite Score.
In addition to the Recurrence Score assay, several other
multiparameter gene expression assays are commercially available
(e.g., MammaPrint®TM, Prosigna™, Breast Cancer Index℠).36
Although these signatures include different genes, they provide
similar prognostic information that is driven largely by prolifera-
tion and estrogen-dependent genes and not by the intrinsic
propensity of tumor cells to metastasize or interact with their
microenvironment.36–39 Although direct comparison of the prog-
nostic classiﬁcation provided by some of these gene expression
assays in the same cohort showed comparable prognostic
information, they often provide discordant recurrence risk
classiﬁcation.33 Since MetaSite Score correlates poorly with
Recurrence Score, captures different biologic information, and
provides complementary prognostic information, it offers the
potential to more accurately determine prognosis when added to
multiparameter gene expression assays.
The tertiles of MetaSite Scores in the entire study population
study were comparable in this clinical trial cohort using a fully
automated assay in a clinical diagnostic laboratory (</=5, 6–17,
>/=18) to the prior population-based cohort using a manual assay
in an academic research laboratory (</=6, 7–22, >/=23);26 an
analytic validation study of the MetaSite Breast™ assay using
samples from the latter cohort yielded similar results.31 A new
ﬁnding of the current study was that MetaSite Score was
prognostic for distant recurrence within 5 years of diagnosis, but
not after, which was not observed in our prior study in a
population-based cohort.26 In E2197, all patients received four
cycles of adjuvant doxorubicin plus cyclophosphamide (AC) or
docetaxel (AT) (which were comparably effective28), whereas only
43% of patients in the population-based cohort received adjuvant
chemotherapy. Since adjuvant chemotherapy (including a more
prolonged course of sequential anthracycline-taxane therapy)
prevents mainly early recurrence within the ﬁrst 5 years, and
sequentially administered regimens of longer duration are
generally more effective than shorter regimens,40 a biomarker
prognostic for early recurrence could be predictive for beneﬁt from
adjuvant chemotherapy, or more prolonged course of sequential
anthracycline-taxane therapy. Moreover, early recurrence is asso-
ciated with more aggressive disease and shorter survival than later
recurrence,41 providing additional evidence that a biomarker
prognostic for early recurrence provides clinically meaningful
information. Additional studies in other cohorts will be required to
determine the optimal MetaSite Score cutpoints for prognosis, and
for prediction of chemotherapy beneﬁt. Furthermore, studies are
ongoing that are evaluating whether an a multiparameter
biomarker that integrates TMEM Score with assessment of invasive
Mena isoforms42,43 improves the accuracy of the prognostic
information provided by the MetaSite Score alone.
Although we have focused on MetaSite Score as a prognostic
biomarker in this study, and also described its potential for
predicting chemotherapy beneﬁt, it may also serve as a biomarker
for agents targeting tumor-stromal interactions. For example, the
TIE2 receptor is highly expressed in the TMEM-associated TIE2Hi/
VEGFHi macrophage, and is responsible for the local release of
VEGF from TMEM-associated macrophages causing vascular
permeability speciﬁcally at TMEM sites.23 This offers the potential
to use TMEM Score and other biomarkers reﬂecting TMEM
function as predictive biomarkers for therapies targeting the
Tie2-VEGF axis; a clinical trial testing this strategy for the ﬁrst time
is currently in progress (NCT02824575).
In conclusion, we report the results of a second prospective-
retrospective validation study demonstrating the clinical validity
of MetaSite Score in patients with ER+/HER2- breast cancer and
show for the ﬁrst time that it provides complementary prognostic
information to Recurrence Score, speciﬁcally for early recurrence
within 5 years of diagnosis. In both the original population-based
cohort26 and the current clinical trial cohort, we used a high-
throughput analytically validated assay (MetaSite Breast™) in a
CLIA-certiﬁed clinical diagnostic laboratory for identiﬁcation and
enumeration of TMEM. Additional studies will be required to
deﬁne the clinical utility of this assay in clinical practice.
METHODS
Study population and treatment
The study utilized tumor specimens and clinical information from patients
enrolled on trial E2197 (ClinicalTrials.gov identiﬁer NCT00003519), coordi-
nated by the Eastern Cooperative Oncology Group (ECOG), details of which
have been reported.28 Brieﬂy, 2952 eligible patients (of whom 2603
consented to future research) were randomly assigned to receive four 3-
week cycles of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2
(AC) or docetaxel 60 mg/m2 (AT). Methods for selection of 776 cases
(enriched for all relapsing cases) in the cohort have been previously
described (including the 600 patients included in this analysis), and
summarized in Supplemental Fig. 2.44–47 All specimens underwent analysis
for tumor grade, and for ER, progesterone receptor (PR), and HER2 protein
expression in a central lab as previously described47 (including HER2
assessment by 2007 ASCO-CAP guidelines used at the time48), and for
Oncotype DX Recurrence Score in the Genomic Health, Inc. (Redwood City,
CA) laboratory. The weighted distributions of the characteristics of the
patients in the sample of 600 cases and the E2197 cases not in the sample
are compared in Supplemental Table 3, indicating that the characteristics
for the included vs. not-in-sample cohorts were similar except for race,
where the weighted percent of whites is higher for those included (91.1%)
compared with those not included (86.4%).
The parent E2197 clinical trial was approved by the institutional review
boards of all participating institutions and was carried out in accordance with
the Declaration of Helsinki, Food and Drug Administration Good Clinical
Practices, and local ethical and legal requirements. The use of specimens for
this project was approved the North American Intergroup Correlative Science
Committee, by the MD Anderson Cancer Center Institutional Review Board
(which oversees the ECOG-ACRIN Central Biorepository and Pathology
Fig. 3 Hazard ratio for recurrence (and 95% conﬁdence intervals) for
MetaSite Score by empirical tertile group by categorical Recurrence
Score, including classical deﬁnitions (3a) and TAILORx deﬁnitions
(3b)
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Facility), and by the Albert Einstein College of Medicine Institutional Review
Board (for the study principal investigator JAS).
MetaSite Breast™ assay
The MetaSite Breast™ assay was for identifying and enumerating TMEM
was performed in a commercial CLIA-certiﬁed laboratory (CLIA ID No.
22D2094085; MetaStat, Inc. Drydock Avenue, Boston MA), as previously
described.31 Brieﬂy, tissue sections (5 um formalin-ﬁxed parafﬁn
embedded on positively charged glass microscope slides) were derived
from tumor blocks at the ECOG-ACRIN Central Biorepository and Pathology
Facility (CBPF), sent to MetaStat, and upon receipt were dipped in parafﬁn
and stored under non-oxidizing and non-hydrolyzing conditions until
stained. Tissue samples were stained using a modiﬁed triple chromogen
immunohistochemical stain for CD31-positive blood vessels using a rabbit
anti-CD31 monoclonal antibody (AbCam/Epitomics Clone EP3095), for
CD68-positive macrophages using an anti-CD68 mouse monoclonal
antibody (Thermo Scientiﬁc Clone PGM1), and for Mena-positive tumor
cells using an anti-Pan-Mena mouse monoclonal antibody (Gertler lab,
MIT). CD31-positive blood vessels were visualized using blue chromogen,
CD68-positive macrophages visualized using brown chromogen, and Mena
using red chromogen. A pathologist reviewed each sample for quality and
speciﬁc staining patterns based on established speciﬁcity criteria in
addition to image capture of invasive cancer alone. Imaging was
conducted using the Perkin Elmer Vectra 2 multispectral microscopy
system (Perkin Elmer, Hopkinton, MA), which allows for spectral un-mixing
of chromogens enabling highly accurate imaging and image analysis. For
whole tissue imaging, up to 100 20X high-resolution images were acquired
in areas of invasive tumor using established and validated image analysis
algorithms. All images used in analysis were reviewed by trained
pathologists for image quality and histologic speciﬁcity. TMEM identiﬁca-
tion and enumeration were accomplished through a combination of
InForm (PerkinElmer) and VisioPharm (VisioPharm) image analysis soft-
ware. InForm generates spectrally unmixed composite images represent-
ing spectrally pure chromogen channels for CD31, CD68, and Pan-Mena.
These images were then used in a VisioPharm MetaSite identiﬁcation
algorithm where TMEM were identiﬁed as microanatomic structures that
meet established criteria for direct contact of all three cells. The number of
TMEM for each image were quantiﬁed and reported as MetaSite Score.
MetaSite Score was deﬁned as the sum of TMEM sites from each of the top
three highest density 20X ﬁelds-of-view. Prior to evaluation of samples
from the E2197 trial, the analytical precision, reproducibility, and accuracy
of the fully automated MetaSite Breast™ clinical assay was demonstrated
in an analytical validation study using formalin-ﬁxed, parafﬁn-embedded
(FFPE) tissue samples from patients with invasive breast cancer.31
Statistical analyses
The primary endpoint for analysis was distant recurrence-free interval
(DRFI), deﬁned as time from entry on E2197 to ﬁrst distant recurrence. DRFI
is censored at the time last known to be free of distant recurrence. Because
only the ﬁrst recurrence of any type was recorded in the database, for
patients with local or regional recurrence (before distant), DRFI is censored
at the date of ﬁrst recurrence. Other endpoints include recurrence-free
interval (RFI), deﬁned to be time from study entry to ﬁrst recurrence of
breast cancer at any site, censored at the date last known to be free of
recurrence, and OS, deﬁned to be the time from entry on E2197 to death
from any cause, censored at the date last known to be alive. DRFI and RFI
were deﬁned in accordance with STEEP guidelines.49 The number of events
for each subgroup, overall and by follow-up time, are shown in
Supplemental Table 2. Because only 37 of 85 deaths (44%) in the HR
+/HER2- group were due to breast cancer, we also evaluated breast cancer
speciﬁc survival, deﬁned as time from study entry until death due to breast
cancer.
As previously described, although a biased sample was used, unbiased
estimates of effect were obtained by weighting the contributions of
observations by the inverse of the sampling fractions in the sampling
groups (the strata by recurrence status combinations).50 While standard
software can be used to compute the weighted estimates, special routines
are often needed to compute correct standard errors. Distributions of the
characteristics of patients were estimated using weighted proportions and
weighted averages. Time to event distributions were estimated using
weighted Kaplan–Meier estimators. Hazard ratios were estimated and
regression analyses performed by ﬁtting weighted partial likelihood
models. All analyses were performed in R 3.2.3. Weighted partial likelihood
models were ﬁt using the coxph() function with weights. A locally written
function was used to compute the corrected variance using the score
residuals from the ﬁtted model. For time-varying coefﬁcient models, start
and stop arguments are used to create data sets for the contribution at
each event time. Evaluation of prognosis associated with categorical
Recurrence Score included the classical deﬁnitions of low, intermediate,
and high (<18, 18–30, >30), and also the deﬁnitions (<11, 11–25, >25) used
in the Trial Assigning Individualized Options for Treatment (TAILORx).29
Based on the assumption that 621 specimens would be available (80% of
original sample of 776 patients), it was estimated that the study would
have 80% power using a two-sided 5% signiﬁcance level to detect a hazard
ratio of 2.0–2.2 associated with DRFI between the highest and the lowest
tertile TMEM Score level, which was comparable to that observed in the
original TMEM validation study (2.70, 95% CI: 1.39, 5.26).26 The study was
conducted in accordance with reporting recommendations for tumor
marker prognostic studies (REMARK) guidelines.51
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